Onconetix, Inc. Files 8-K: Material Agreement & Equity Sales
Ticker: ONCO · Form: 8-K · Filed: Oct 3, 2025
Sentiment: neutral
Topics: material-agreement, equity-sale, financials
Related Tickers: ONCO
TL;DR
Onconetix (ONCO) filed an 8-K for Oct 1st - material agreement and equity sales. Watch closely.
AI Summary
Onconetix, Inc. reported on October 3, 2025, regarding events that occurred on October 1, 2025. The filing indicates an entry into a material definitive agreement and unregistered sales of equity securities. It also includes financial statements and exhibits.
Why It Matters
This 8-K filing signals significant corporate activity for Onconetix, Inc., potentially impacting its financial structure and future operations.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and unregistered equity sales, which can introduce financial and operational risks.
Key Players & Entities
- Onconetix, Inc. (company) — Registrant
- October 1, 2025 (date) — Earliest event date
- October 3, 2025 (date) — Report date
- Blue Water Biotech, Inc. (company) — Former company name
- Blue Water Vaccines Inc. (company) — Former company name
FAQ
What is the nature of the material definitive agreement entered into by Onconetix, Inc. on October 1, 2025?
The filing indicates an entry into a material definitive agreement, but the specific details of the agreement are not provided in the provided text.
What type of equity securities were sold in the unregistered sales reported by Onconetix, Inc.?
The filing mentions unregistered sales of equity securities, but the specific type and details of these securities are not detailed in the provided text.
What are the key financial statements and exhibits included with this 8-K filing?
The filing states that financial statements and exhibits are included, but the specific content is not detailed in the provided text.
When did Onconetix, Inc. change its name from Blue Water Biotech, Inc.?
Onconetix, Inc. changed its name from Blue Water Biotech, Inc. on April 24, 2023.
What is the Standard Industrial Classification code for Onconetix, Inc.?
The Standard Industrial Classification code for Onconetix, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 4,827 words · 19 min read · ~16 pages · Grade level 20 · Accepted 2025-10-03 08:16:13
Key Financial Figures
- $0.00001 — ch Registered Common Stock, par value $0.00001 per share ONCO The Nasdaq Stock Mar
- $6.25 million — gregate purchase price of approximately $6.25 million. Such investment is referred to as the
- $1,000 — ed Stock, each having a stated value of $1,000 per share (the " Stated Value "). Rank
- $3 — on Date or other date of determination, $3.8576, subject to adjustment as provided
- $0.7715 — uring Period. 2 " Floor Price " means $0.7715 (as adjusted for stock splits, stock di
- $500,000 — to maturity of at least an aggregate of $500,000 of Indebtedness of the Company or any o
Filing Documents
- ea0259860-8k_onconetix.htm (8-K) — 84KB
- ea025986001ex3-1_onconetix.htm (EX-3.1) — 311KB
- ea025986001ex4-1_onconetix.htm (EX-4.1) — 181KB
- ea025986001ex10-1_onconetix.htm (EX-10.1) — 291KB
- ea025986001ex10-2_onconetix.htm (EX-10.2) — 173KB
- 0001213900-25-095847.txt ( ) — 1463KB
- onco-20251001.xsd (EX-101.SCH) — 3KB
- onco-20251001_lab.xml (EX-101.LAB) — 33KB
- onco-20251001_pre.xml (EX-101.PRE) — 22KB
- ea0259860-8k_onconetix_htm.xml (XML) — 4KB
01. Entry into a Material Definitive
Item 1.01. Entry into a Material Definitive Agreement. PIPE Financing On October 1, 2025, Onconetix, Inc., a Delaware corporation (the " Company "), entered into, and sold to institutional investor(s) (collectively, the " PIPE Investors "), pursuant to a securities purchase agreement (the " Securities Purchase Agreement ") an aggregate of 7,813 shares of Series E convertible preferred stock, par value $0.00001 per share (" Series E Preferred Stock "), which are convertible into common stock of the Company, $0.00001 par value per share (the " Common Stock ") and warrants to purchase 2,025,223 shares of Common Stock (the " Warrants " and, together with the Series E Preferred Stock, the " PIPE Securities "), for an aggregate purchase price of approximately $6.25 million. Such investment is referred to as the " PIPE Financing ." Concurrently with entering into the Securities Purchase Agreement, the Company also entered into a registration rights agreement with the PIPE Investors, pursuant to which it has agreed to provide the PIPE Investors with certain registration rights related to the shares of Common Stock underlying the shares of Series E Preferred Stock (the " Preferred Shares ") and Warrants, as described below. The following description of the terms of the Securities Purchase Agreement and the Certificate of Designations of Preferences, Rights and Limitations of the Series E Preferred Stock (the " Certificate of Designations "), Warrants and Registration Rights Agreement are only summaries and do not purport to be complete and are qualified in their entirety by reference to the full text of each of those transaction documents, copies of which are filed as Exhibits 10.1, 3.1, 4.1 and 10.2, respectively, to this Current Report on Form 8-K, and are incorporated by reference herein. Capitalized terms used but not defined herein will have the meanings assigned to them in the Securities Purchase Agreement, Certificate of Designations, Warrants or Registration Rig